


## FORM PTO-1449



U.S. PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCK. NO.  
225/273SERIAL NO.  
08/872,527APPLICANT:  
Dr. Yajun GuoFILING DATE:  
6/11/97GROUP:  
1644

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
TC	AA	4,844,893	7/4/89	Honsik, et al.	—	—	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
							YES NO
	AL						
	AM						
	AN						
	AO						
	AP						


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TC	AQ		Shi, et al. "Adoptive Immunotherapy for Hepatocellular Carcinoma with Tumor Specific CTLs Generated <i>In Vitro</i> by Stimulating TILs or PBLs with the Cytokine Treated Tumor Cells and a Bispecific Monoclonal Antibody" <i>Proc. Am. Assoc. Cancer Res.</i> 37: 480, Abstract No. 3278 (1996)
TC	AR	✓	Guo, et al. "Effective Tumor Vaccines Generated by <i>In Vitro</i> Modification of Tumor Cells With Cytokines and Bispecific Monoclonal Antibodies" <i>Nature Medicine</i> 3(4): 451-455 (1997)
TC	AS	✓	Azuma, et al. "Induction of Intracellular Adhesion Molecule 1 on Small Cell Carcinoma Cell Lines by Gamma-Interferon Enhances Spontaneous and Bispecific Anti-CD3 X Antitumor Antibody-directed Lymphokine-activated Killer Cell Cytotoxicity" <i>Cancer Research</i> 52: 4890-4894 (1992)
TC	AT	✓	Demanet, et al. "Bispecific Antibody-mediated Immunotherapy of the BCL1 Lymphoma: Increased Efficacy with Multiple Injections and CD28-Induced Costimulation" <i>Blood</i> 87(10): 4390-4398 (1996)
TC	AU	✓	Hombach, et al. "Specific Activation of Resting T Cells Against Tumour Cells by Bispecific Antibodies and CD28-Mediated Costimulation is Accompanied by Th1 Differentiation and Recruitment of MHC-independent Cytotoxicity" <i>Clinical and Experimental Immunology</i> 108: 352-357 (1997)
	AV		

*TC*

4/22/98

FORM PTO-1449



STATEMENT OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

ATTY. DOCKET NO. 225/273	SERIAL NO. 08/872,527
APPLICANT: Dr. Yajun Guo	
FILING DATE: June 11, 1997	GROUP: Unassigned 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TC DUO	AX	Guo, <i>et al.</i> "Effective Tumor Vaccine Generated by Fusion of Hepatoma Cells with Activated B Cells" <i>Science</i> 263:518-520 (1994)
	AY	Leach, <i>et al.</i> "Enhancement of Antitumor Immunity by CTLA-4 Blockade" <i>Science</i> 271:1734-1736 (1996)
	AZ	Takahashi, <i>et al.</i> "Inhibition of Human Colon Cancer Growth by Antibody-Directed Human LAK Cells in SCID Mice" <i>Science</i> 259:1460-1463 (1993)
	BA	Luboldt, <i>et al.</i> "Selective Loss of Human Leukocyte Antigen Class I Allele Expression in Advanced Renal Cell Carcinoma" <i>Cancer Research</i> 56:826-830 (1996)
	BB	Nitta, <i>et al.</i> "Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells" <i>J. Neurosurg.</i> 72:476-481 (1990)
	BC	Renner, <i>et al.</i> "Cure of Xenografted Human Tumors by Biospecific Monoclonal Antibodies and Human T Cells" <i>Science</i> 264:833-835 (1994)
	BD	Bohlen, <i>et al.</i> "Lysis of Malignant B Cells From Patients With B-Chronic Lymphocytic Leukemia by Autologous T Cells Activated with CD3 x CD19 Bispecific Antibodies in Combination With Bivalent CD28 Antibodies" <i>Blood</i> 82(6):1803-1812 (1993)
	BE	Shen, <i>et al.</i> "Cloned Dendritic Cells Can Present Exogenous Antigens on Both MHC Class I and Class II Molecules" <i>J. Immunol.</i> 158:2723-2730 (1997)
	BF	Cayeux, <i>et al.</i> "Influence of Gene-Modified (IL-7, IL-4, and B7) Tumor Cell Vaccines on Tumor Antigen Presentation" <i>J. Immunol.</i> 158:2834-2841 (1997)
	BG	Keane-Myers, <i>et al.</i> "B7-CD28/CTLA-4 Costimulatory Pathways Are Required for the Development of T Helper Cell 2-Mediated Allergic Airway Responses to Inhaled Antigens" <i>J. Immunol.</i> 158:2042-2049 (1997)
	BH	Hunter, <i>et al.</i> "The Role of the CD28/B7 Interaction in the Regulation of NK Cell Responses During Infection with <i>Toxoplasma gondii</i> " <i>J. Immunol.</i> 158:2285-2293 (1997)
	BI	Svensson, <i>et al.</i> "Bone Marrow-Derived Dendritic Cells Can Process Bacteria for MHC-I and MHC-II Presentation to T Cells" <i>J. Immunol.</i> 158:4229-4236 (1997)
	BJ	Lakkis, <i>et al.</i> "Blocking the CD28-B7 Cell Costimulation Pathway Induces Long Term Cardiac Allograft Acceptance in the Absence of IL-4" <i>J. Immunol.</i> 158:2443-1448 (1997)
	BK	Ranheim, <i>et al.</i> "Activated T Cells Induce Expression of B7/BB1 on Normal or Leukemic B Cells through a CD40-dependent Signal" <i>J. Exp. Med.</i> 177:925-935 (1993)
	BL	Azuma, <i>et al.</i> "B70 antigen is a second ligand for CTLA-4 and CD28" <i>Nature</i> 366:76-79 (1993)
	BM	Sethna, <i>et al.</i> "A Negative Regulatory Function of B7 Revealed in B7-1 Transgenic Mice" <i>Immunity</i> 1:415-421 (1994)
	BN	Green, <i>et al.</i> "Absence of B7-Dependent Responses in CD28-Deficient Mice" <i>Immunity</i> 1:501-508 (1994)
	BO	Townsend, <i>et al.</i> "Tumor Rejection After Direct Costimulation of CD8 <sup>+</sup> T Cells by B7-Transfected Melanoma Cells" <i>Science</i> 259:368-370 (1993)
	BP	Walunas, <i>et al.</i> "CTLA-4 Can Function as a Negative Regulator of T Cell Activation" <i>Immunity</i> 1:405-413 (1994)
JK MHD	BQ	Grabbe, <i>et al.</i> "Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy" <i>Trends</i> 16(3):117-121 (1995)

## LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.  
225/273SERIAL NO.  
08-872,527APPLICANT:  
Dr. Yajun Guo

G

FILING DATE:  
June 11, 1997GROUP:  
Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PD TC	AQ	Bohlen, <i>et al.</i> "Prevention of Epstein-Barr Virus-induced Human B-Cell Lymphoma in Severe Combined Immunodeficient Mice Treated with CD3xCD19 Bispecific Antibodies, CD28 Monospecific Antibodies, and Autologous T Cells" <i>Cancer Research</i> 57:1704-1709 (1997)
TC	AR	Gaczynska, <i>et al.</i> "γ-Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes" <i>Nature</i> 365:264-266 (1993)
TC	AS	Gong, <i>et al.</i> "Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells" <i>Nature Medicine</i> 3(5):558-561 (1997)
TC	AT	Chen, <i>et al.</i> "Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4" <i>Cell</i> 71:1093-1102 (1992)
TC	AU	Hsu, <i>et al.</i> "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells" <i>Nature Medicine</i> 2(1):52-58 (1996)
TC	AV	Nitta, <i>et al.</i> "Bispecific F(ab') <sub>2</sub> monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytotoxicity of human T cells" <i>Eur. J. Immunol.</i> 19:1437-1441 (1989)
TC	AW	Chapoval, <i>et al.</i> "Anti-CD3 x Anti-Tumor F(ab') <sub>2</sub> , Bifunctional Antibody Activates and Retargets Tumor-Infiltrating Lymphocytes" <i>J. Immunol.</i> pp. 1296-1303 (1995)

FORM PTO-1449

U.S. PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKE. NO.  
225/273SERIAL NO.  
08/872,527APPLICANT:  
Dr. Yajun GuoFILING DATE:  
June 11, 1997GROUP:  
Unassigned (64<sup>4</sup>)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

NYC	BR		Yang, <i>et al.</i> "Antitumor Immunity Elicited by Tumor Cells Transfected with B7-2, a Second Ligand for CD28/CTLA-4 Costimulatory Molecules" <i>J. Immunol.</i> 154:2794-2800 (1995)
	BS	✓	Chen, <i>et al.</i> "Tumor Immunogenicity Determines the Effect of B7 Costimulation of T Cell-mediated Tumor Immunity" <i>J. Exp. Med.</i> 179:523-532 (1994)
	BT	✓	Li, <i>et al.</i> "Costimulation of Tumor-Reactive CD4 <sup>+</sup> and CD8 <sup>+</sup> T Lymphocytes by B7, a Natural Ligand for CD28, Can Be Used to Treat Established Mouse Melanoma" <i>J. Immunol.</i> 153:421 (1994)
	BU		Boussiatis, <i>et al.</i> "Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance" <i>J. Immunol.</i> 6:797-807 (1994)
	BV		Ohnishi, <i>et al.</i> "CD28 Cross-Linking Augments TCR-Mediated Signals and Costimulates Superantigen Responses" <i>J. Immunol.</i> 154:3180-3193 (1995)
	BW		Darlington, <i>et al.</i> "Expression of Liver Phenotypes in Cultured Mouse Hepatoma Cells" <i>JNCI</i> 64(4):809-815 (1980)
	BX		Linsley, "Distinct roles for CD28 and Cytotoxic T Lymphocyte-associated Molecule-4 Receptors during T Cell Activation" <i>J. Exp. Med.</i> 182:289-292 (1995)
	BY		Yang, <i>et al.</i> "In Vitro Priming of Tumor-Reactive Cytolytic T Lymphocytes by Combining IL-10 with B7-CD28 Costimulation" <i>J. Immunol.</i> 155:3897-3903 (1995)
	BZ		Li, <i>et al.</i> "Costimulation by CD48 and B7-1 Induces Immunity against Poorly Immunogenic Tumors" <i>J. Exp. Med.</i> 183:639-644 (1996)
	CA		MacLean, <i>et al.</i> "Anti-CD3:Anti-IL-2 Receptor-Bispecific mAb-Mediated Immunomodulation" <i>J. Immunol.</i> 155:3674-3682 (1995)
	CB		Chen, <i>et al.</i> "Potent antitumor activity of a new class of tumour-specific killer cells" <i>Nature</i> 385:78-80 (1997)
	CC		Huang, <i>et al.</i> "Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens" <i>Science</i> 264:961-965 (1994)
	CD		Lanzavecchia, <i>et al.</i> "The use of hybrid hybridomas to target human cytotoxic T lymphocytes" <i>Eur. J. Immunol.</i> 17:105-111 (1987)
	CE		Krummel, <i>et al.</i> "CD28 and CTLA-4 Have Opposing Effects on the Response of T Cells to Stimulation" <i>J. Exp. Med.</i> 182:459-465 (1995)
	CF		Linsley, "Distinct roles for CD28 and Cytotoxic T Lymphocyte-associated Molecule-4 Receptors during T Cell Activation" <i>J. Exp. Med.</i> 182:289-292 (1995)
	CG		Li, <i>et al.</i> "Costimulation by CD48 and B7-1 Induces Immunity against Poorly Immunogenic Tumors" <i>J. Exp. Med.</i> 183:639-644 (1996)
	CH		Cohen "Mounting a Targeted Strike on Unwanted Immune Responses" <i>Science</i> 257:751 (1992)
	CI		Grabbe, <i>et al.</i> "Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?" <i>Trends</i> 16(3):117-121 (1995)
	CJ		Greenfield, <i>et al.</i> "B7.2 Expressed by T Cells Does Not Induce CD28-Mediated Costimulatory Activity but Retains CTLA4 Binding" <i>J. Immunol.</i> 158:2025-2034 (1997)
NYC	CK		Bluestone "Is CTLA-4 a Master Switch for Peripherial T Cell Tolerance? <i>J. Immunol.</i> 158:1989-1993 (1997)